Trial Pharma Kft.

At Trial Pharma Kft. in Gyula, Hungary, clinical research in cardiovascular diseases focuses on conditions such as atrial fibrillation, atherosclerotic cardiovascular disease, and broader cardiovascular disease risk. These studies are designed to evaluate new approaches for preventing major events like stroke, heart attack, and cardiovascular death, while also assessing overall treatment benefit and safety.

• Prevention of stroke and systemic embolism in atrial fibrillation
• Reduction of cardiovascular morbidity and mortality in high-risk patients
• Lowering the risk of first major cardiovascular events linked to elevated lipoprotein(a)

The site also supports research aimed at improving long-term cardiovascular protection in people with overweight or obesity.

Research in respiratory tract diseases includes studies in chronic obstructive pulmonary disease and asthma. These trials are evaluating new treatment combinations and inhaled therapies to help reduce exacerbations, improve lung function, and support better daily control of chronic breathing conditions.

• Chronic obstructive pulmonary disease and chronic bronchitis
• Mild to moderate asthma
• Severe flare-up prevention and symptom control

The respiratory program at Trial Pharma Kft. is centered on improving effectiveness and tolerability of maintenance treatment for patients with long-term airway disease.

Clinical studies in immune system diseases cover inflammatory and autoimmune conditions such as atopic dermatitis, vitiligo, and Graves’ disease. The main goal is to test new therapies that may better control immune-driven symptoms, improve skin or thyroid-related outcomes, and offer longer-term safety data.

• Moderate-to-severe atopic dermatitis
• Nonsegmental vitiligo
• Graves’ disease and thyroid autoimmunity

These trials reflect a strong interest in both immune-mediated skin disease and autoimmune endocrine disorders.

Work in nutritional and metabolic diseases includes studies of obesity, non-alcoholic steatohepatitis, and related cardiometabolic risk. The research is aimed at testing treatments that may help slow disease progression, improve metabolic health, and reduce the burden of complications affecting the liver and heart.

• Obesity and overweight-related complications
• Non-alcoholic steatohepatitis and liver injury
• Cardiometabolic risk reduction

Several studies at the site explore whether new therapies can improve both metabolic control and long-term health outcomes.

Within digestive system diseases, the main focus is non-alcoholic steatohepatitis, a serious liver condition linked to metabolic dysfunction. The trials are intended to assess whether investigational treatments can resolve inflammation, limit fibrosis, and help prevent worsening liver damage over time.

• Non-alcoholic steatohepatitis
• Fibrosis improvement and disease resolution
• Long-term liver health monitoring

This area highlights the site’s role in advancing treatment options for chronic liver disease.

Research in skin and connective tissue diseases focuses on chronic inflammatory skin disorders, especially atopic dermatitis and vitiligo. These studies are evaluating therapies intended to reduce itching, inflammation, and visible skin changes, while also tracking safety and durability of response.

• Moderate-to-severe atopic dermatitis in children, adolescents, and adults
• Nonsegmental vitiligo
• Long-term symptom control and tolerability

The dermatology research portfolio at Trial Pharma Kft. supports both short-term symptom improvement and longer-term management of chronic skin disease.